MarketFriction

Sun Pharmaceutical Industries Ltd

NSE SUNPHARMA · BSE 524715 · Pharmaceuticals
₹1,801.00 -0.86%
NSE close2026-10-01
52 week range1,583.70 - 2,046.90
Market cap₹4,47,476 Cr.
P/E35.4
Nifty 50Nifty 100Nifty 200Nifty 500Nifty PharmaNifty Healthcare Index No price band Delivery 64.0%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales12,19212,38111,98312,65313,29113,67512,95913,85114,47815,52114,61215,300
Expenses9,0138,9048,9489,0459,3529,6669,2439,5509,95110,57210,65810,882
Operating Profit3,1793,4773,0353,6083,9394,0093,7164,3024,5274,9483,9544,418
OPM %26%28%25%29%30%29%29%31%31%32%27%29%
Other Income294180504533354149251-35447089458520
Interest49357462695249751007886100
Depreciation633622650655626631664701730732775739
Profit before tax2,7913,0002,8163,4243,5983,4763,2543,1734,1684,2273,5514,099
Tax %14%14%5%16%16%16%34%27%25%20%23%29%
Net Profit2,3852,5612,6592,8613,0372,9132,1542,2933,1253,3812,7102,901
EPS in Rs9.9010.5211.0611.8212.6712.108.969.5013.0014.0411.3112.06
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales28,48731,57826,48929,06632,83833,49838,65443,88648,49752,57858,46259,911
Expenses20,31321,47620,85822,68925,85525,02828,39732,23535,47937,46441,96142,063
Operating Profit8,17410,1025,6316,3776,9838,47010,25811,65013,01815,11416,50117,847
OPM %29%32%21%22%21%25%27%27%27%29%28%30%
Other Income-42610-135-258382-3,449-3,5054598651,4441,8951,537
Interest523400518555303141127172238231339364
Depreciation1,0381,2651,5001,7532,0532,0802,1442,5292,5572,5752,9382,976
Profit before tax6,5719,0483,4793,8105,0102,7994,4819,40811,08813,75215,11916,045
Tax %14%13%26%16%16%18%24%9%13%20%24%
Net Profit5,6587,8462,5423,2084,1722,2723,3898,5139,61010,96511,50912,117
EPS in Rs18.8929.038.7311.1115.6912.1013.6435.3239.9145.5547.8450.41
Dividend Payout %5%12%23%25%25%62%73%33%34%35%33%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth7%12%10%11%
Compounded Profit Growth10%17%13%10%
Stock Price CAGR10%18%17%17%
Return on Equity14%16%16%16%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital207241240240240240240240240240240240
Reserves25,43132,74236,40038,07441,16945,02546,22347,77155,75563,42771,97883,330
Borrowings8,9968,4979,83210,38510,5148,3153,8691,2906,8863,2742,3624,627
Other Liabilities14,08913,94814,62415,59812,66614,61517,29120,47417,83118,38717,32820,210
Total Liabilities48,72355,42861,09564,29764,59068,19467,62269,77680,71285,32891,908108,407
Fixed Assets12,68215,87217,67518,85321,83722,84721,55322,66524,06523,24822,58632,822
CWIP2,0392,1752,8012,4651,4111,2201,5671,2874,9735,3546,6443,052
Investments2,7161,8301,1927,1437,90310,1439,61212,84914,82415,02618,35424,723
Other Assets31,28635,55039,42735,83733,43933,98434,89032,97536,84941,70044,32447,811
Total Assets48,72355,42861,09564,29764,59068,19467,62269,77680,71285,32891,908108,407
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity5,6166,6867,0823,9072,1966,5556,1708,9854,95912,13514,07212,419
Cash from Investing Activity-1,502-3,949-4,186-3,104-310-2,225407-5,556-7,220-763-5,183-10,405
Cash from Financing Activity-1,187-1,889-2,285-1,539-2,731-5,715-5,980-5,1932,376-6,710-7,906-2,513
Net Cash Flow2,927848611-736-844-1,386596-1,7651154,662983-498
Free Cash Flow3,3163,3533,4922,013-9665,1055,0977,5502,8959,96412,0058,906
CFO/OP93%106%90%83%48%113%85%78%56%105%96%89%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days688783108112105999995859197
Inventory Days307370307338366311378315360338348363
Days Payable178207197234192142167158194194210232
Cash Conversion Cycle197251193212285274310255261229228228
Working Capital Days-737-4-313151514740556554
ROCE %23%18%20%10%10%10%13%17%16%17%20%21%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%
FIIs16.78%17.08%17.72%17.23%18.01%18.04%17.96%17.26%16.55%16.12%15.94%14.54%
DIIs19.56%19.42%18.71%19.17%18.48%18.43%18.58%19.38%20.12%20.72%21.00%22.06%
Government0.10%0.11%0.11%0.11%0.11%0.11%0.11%0.11%0.11%0.11%0.11%0.11%
Public9.05%8.92%8.97%9.00%8.89%8.92%8.86%8.76%8.72%8.57%8.48%8.81%
No. of Shareholders6,16,5886,12,6266,31,3926,73,2176,57,3176,89,6237,04,9837,23,7707,43,8777,10,9006,90,9577,10,246

Fundamentals

Market Cap₹ 4,47,476 Cr.
Current Price₹ 1,865
Stock P/E35.4
Book Value₹ 348
ROCE20.5 %
ROE16.0 %
Dividend Yield0.86 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)11%
Compounded Profit Growth (TTM)10%
Consolidated figures.
Valuation
Market capRs 432,120 Cr
Enterprise valueRs 425,144 Cr
P/E (TTM)35.73x
Price to book5.17x
Price to sales7.21x
EV / EBITDA21.93x
EV / EBIT25.91x
EV / sales7.10x
Price to cash flow34.79x
Earnings yield2.80%
Dividend yield0.89%
P/E, 3-year average38.47x
P/B, 3-year average5.64x
P/E, 5-year average42.06x
P/B, 5-year average5.14x
Profitability
Operating margin (excl. other income)28.22%
Operating margin (incl. other income)31.47%
EBITDA margin32.36%
Pre-tax margin26.78%
Net profit margin20.19%
Net margin, latest quarter18.92%
ROE14.74%
ROCE18.99%
ROA11.46%
ROE, 3-year average15.61%
ROCE, 3-year average18.73%
ROA, 3-year average11.78%
ROE, 5-year average14.01%
ROCE, 5-year average16.51%
ROA, 5-year average10.27%
ROIC (approx.)16.39%
Tax rate23.51%
Other income / net worth2.27%
Growth
Sales growth (latest year)11.19%
Profit growth (latest year)5.04%
Sales CAGR, 3 years10.03%
Sales CAGR, 5 years11.78%
Profit CAGR, 3 years10.65%
Profit CAGR, 5 years31.64%
Sales growth QoQ4.71%
Profit growth QoQ6.66%
Sales growth YoY (latest quarter)10.46%
Profit growth YoY (latest quarter)27.04%
Per share
EPS (TTM)Rs 50.41
EPS (latest year)Rs 47.84
EPS (latest quarter)Rs 12.06
EPS, 3-year averageRs 44.44
EPS, 5-year averageRs 36.45
Book value per shareRs 348.31
Sales per shareRs 249.70
Cash flow per shareRs 51.76
Free cash flow per shareRs 37.12
Dividend per share (latest year)Rs 16.00
Dividend per share, 3-year averageRs 15.17
Dividend per share, 5-year averageRs 13.40
Dividends
Dividend payout33.44%
Dividend payout, 3-year average34.13%
Dividend payout, 5-year average41.65%
Efficiency
Asset turnover0.54x
Fixed asset turnover1.78x
Inventory turnover1.30x
Inventory days281 days
Debtor days97 days
Debtors turnover3.77x
Creditor days232 days
Cash conversion cycle228 days
Working capital days54 days
Leverage
Total debtRs 4,627 Cr
Cash and bankRs 11,603 Cr
Net debtRs -6,976 Cr
Debt to equity0.06x
Net debt / EBITDA-0.36x
Interest coverage45.11x
Current ratio (filing 2026-03-31)2.82x
Quick ratio (filing 2026-03-31)2.31x
Trade payables (filing 2026-03-31)Rs 7,334 Cr
Owners' fund to total sources77.09%
Debt to assets4.27%
Cash flow
Cash from Operating Activity (latest year)Rs 12,419 Cr
Cash from Investing Activity (latest year)Rs -10,405 Cr
Cash from Financing Activity (latest year)Rs -2,513 Cr
Net Cash Flow (latest year)Rs -498 Cr
Free cash flow (latest year)Rs 8,906 Cr
FCFE (approx.: FCF + change in debt)Rs 11,171 Cr
Cash from ops / profit, 5 years1.20x
Sales to cash flow4.71x
Statement figures
Net sales (TTM)Rs 59,911 Cr
Net sales (latest year)Rs 58,462 Cr
Sales (latest quarter)Rs 15,300 Cr
Operating profit excl. other income (latest year)Rs 16,501 Cr
Operating profit (latest quarter)Rs 4,418 Cr
Other income (TTM)Rs 1,537 Cr
EBITDA (TTM)Rs 19,385 Cr
PBDT (TTM)Rs 19,021 Cr
Profit before tax (TTM)Rs 16,045 Cr
Tax (latest year)Rs 3,554 Cr
Net profit (TTM)Rs 12,096 Cr
Net profit (latest year)Rs 11,479 Cr
Net profit (latest quarter)Rs 2,895 Cr
Depreciation (TTM)Rs 2,976 Cr
Depreciation (latest quarter)Rs 739 Cr
Interest (TTM)Rs 364 Cr
Cost of goods sold (latest year)Rs 14,922 Cr
Total expenditure (latest year)Rs 41,961 Cr
Total income (latest year)Rs 60,357 Cr
Share capitalRs 240 Cr
ReservesRs 83,330 Cr
Shareholders' fundsRs 83,570 Cr
Total assetsRs 108,407 Cr
Net blockRs 32,822 Cr
Capital work in progressRs 3,052 Cr
InvestmentsRs 24,723 Cr
ReceivablesRs 15,510 Cr
InventoryRs 11,493 Cr
Other liabilitiesRs 20,210 Cr
Shares outstanding (crore)239.93
Ownership
Promoter holding54.48% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 35.7 is at the 26th percentile of its own 9.4-year range (median 39.8, low 16.6, high 76.7).
P/B 5.17 is at the 66th percentile (median 4.36).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodSUNPHARMANifty 50Difference
1 week-2.6%-2.8% +0.1 pts
1 month-6.6%-6.8% +0.2 pts
3 months-5.4%-7.6% +2.2 pts
6 months+2.5%+0.4% +2.1 pts
1 year+10.7%-9.9% +20.6 pts
2 years-3.3%-13.6% +10.2 pts
3 years+55.4%+14.2% +41.3 pts
5 years+117.9%+27.9% +90.0 pts
484 mutual fund schemes hold about ₹48,184 Cr. Over three months 337 bought more and 83 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
ICICI Pru Value Fund4.55%2,733 +1%
ICICI Pru Aggressive Hybrid Fund(A3.73%1,956 +9%
ICICI Pru Large Cap Fund2.24%1,800 -6%
HDFC Balanced Advantage Fund1.54%1,657 +12%
Nippon India Large Cap Fund2.26%1,222 -15%
Kotak Flexi Cap Fund2.11%1,191 +109%
Kotak Flexi Cap Fund2.11%1,185 +109%
HDFC Focused Fund4.19%1,180 +100%
Nippon India Pharma Fund12.37%1,172 +2%
SBI Large Cap Fundd1.98%1,089 +13%
ICICI Pru Multi Asset Allocation Fund1.06%930 -9%
ICICI Pru Equity Savings Fund(Q5.65%914 +2%
ICICI Pru Healthcare Fund-12.31%861 +7%
Axis Large Cap Fund2.61%818 -7%
SBI Balanced Advantage Fund1.77%748 +12%
ICICI Pru India Opp Fund1.88%720 -45%
SBI Healthcare Opp Fund12.33%715 +17%
ICICI Pru ELSS-Tax Saver Fund4.86%695 -1%
Kotak Multi Cap Fund2.31%676 +100%
Kotak Large & Mid Cap Fund1.97%635 +9%
Mirae Asset ELSS Tax Saver Fund2.38%628 +7%
SBI Aggressive Hybrid Fund0.67%595 +100%
Mirae Asset Large & Midcap Fund1.29%589 -8%
Franklin India Focused Equity Fund5.09%586 +12%
UTI Nifty 50 Index Fund1.91%562 +12%

Red flags

F-score 4 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2023-08-28RAKSHA VALIA-Person Acting in ConcPromoter Groupother2,020,000Rs 225.63 CrOff Market
2023-05-22RAKSHA VALIA-Person Acting in ConcPromoter Groupother1,000,000Rs 93.75 CrOff Market
2023-03-27ADITYA MEDISALES LIMITEDPromoter Groupother5,990,000Rs 589.39 CrOff Market
2023-03-20RAKSHA VALIA-Person Acting in ConcImmediate relativeother1,650,000Rs 158.60 CrOff Market
2023-03-16Sailesh T. DesaiDirectorsell4,000Rs 0.39 CrMarket Sale
2023-03-06Shanghvi Finance Private LimiedPromoter Groupother119,837Rs 11.57 CrOff Market
2023-03-03RAKSHA VALIA-Person Acting in ConcImmediate relativeother1,160,000Rs 112.16 CrOff Market
2023-03-01RAKSHA VALIA-Person Acting in ConcImmediate relativeother8,101,000Rs 777.13 CrOff Market
2023-02-22RAKSHA VALIA-Person Acting in ConcImmediate relativeother2,420,000Rs 234.39 CrOff Market
2023-02-22RAKSHA VALIA-Person Acting in ConcImmediate relativeother1,190,000Rs 115.26 CrOff Market
2023-02-17Sailesh T. DesaiKey Managerial Personnelother15,000Rs 1.49 CrOff Market
2023-02-06ADITYA MEDISALES LIMITEDPromoter Groupother6,000,000Rs 614.10 CrOff Market
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹15,300 Cr +10.5% vs Jun 2025. Net profit ₹2,901 Cr +26.5%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-07Dividend - Rs 5 Per Share
2026-02-05Interim Dividend - Rs 11 Per Share
2025-07-07Dividend - Rs 5.50 Per Share
2025-02-06Interim Dividend - Rs 10.50 Per Share
2024-07-12Dividend - Rs 5 Per Share
2024-02-09Interim Dividend - Rs 8.50 Per Share
2023-07-28Dividend - Rs 4 Per Share
2023-02-08Interim Dividend - Rs 7.50 Per Share
2022-08-19Dividend - Rs 3 Per Share
2022-02-09Interim Dividend - Rs 7 Per Share
2021-08-23 Annual General Meeting/Dividend - Rs 2 Per Share
2021-02-09 Interim Dividend - Rs 5.50 Per Share
2020-08-19 Annual General Meeting/Dividend - Re 1 Per Share
2020-02-17 Interim Dividend - Rs 3 Per Share
2019-08-20 Annual General Meeting/Dividend - Rs 2.75 Per Share
2018-09-17 Annual General Meeting/Dividend Rs 2 Per Share
2017-09-18 Annual General Meeting/Dividend - Rs 3.50 Per Share
2016-09-08 Annual General Meeting/Dividend Re 1/- Per Share
2016-07-14 Buy Back
2015-10-21 Annual General Meeting/ Dividend - Rs 3/- Per Share
2014-09-11Annual General Meeting / Dividend - Rs 1.50/- Per Share
2013-09-19Annual General Meeting / Dividend - Rs 2.50/- Per Share
2013-07-29Bonus 1:10.5000
2012-10-31Annual General Meeting
2012-08-14Interim Dividend Rs.4.25 Per Share (Purpose Revised)
2011-09-02Annual General Meeting And Dividend Rs.3.50 Per Share
2010-11-25Face Value Split From Rs.5/- To Re.1/-0.2000
2010-09-09Dividend-Rs.13.75 Per Share
2009-08-21Div-Rs.13.75 Per Share
2008-08-25Dividend - 210%
2007-08-28Agm
2007-04-23Scheme Of Arrangement
2007-03-15Interim Dividend-135% Purpose Revised
2006-09-06Agm/Dividend-110%
DateTypeWhat it says
2026-10-01Shareholder meetingNotice of Postal Ballot October 2026
2026-10-01Press ReleaseA press release dated October 01, 2026, titled "New LEQSELVI® (deuruxolitinib) Two-YearData in Severe Alopecia Areata Showed Sustained Efficacy and Sa...
2026-09-29UpdatesESG Overview for FY 2025-26.
2026-09-28UpdatesCompletion and Result of Postal Ballot dated 25 August 2026.
2026-09-28Press ReleaseA press release for Lerodalcibep licensing agreement.
2026-09-26General UpdatesReceipt of approval of the shareholders for reclassification of shareholder category
2026-09-22Investor PresentationInvestor Presentation
2026-09-11General UpdatesIntimation under Regulation 30 of SEBI LODR
2026-09-09General UpdatesIncorporation of a Subsidiary Company
2026-09-08Credit Rating- NewInternational Credit Ratings
2026-09-03Concall / analyst meetSchedule of meet
2026-09-01Press ReleaseA press release dated September 01, 2026, titled "Sun Pharma Participates in White House Signing Ceremony Highlighting U.S. Medicines Pricing and Acce...
2026-08-25Shareholder meetingNotice of Postal Ballot
2026-08-25Concall / analyst meetSchedule of meet
2026-08-17General UpdatesUpdate on Lipitor Antitrust Litigation
2026-08-06General UpdatesReceipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter Group
2026-08-06Concall / analyst meetTranscript
2026-08-05Concall / analyst meetSchedule of meet
2026-08-05Credit RatingCredit Rating
2026-07-31General UpdatesVoting Results and Scrutinizer Report of 34th AGM held on 31 July 2026
2026-07-31Shareholder meetingOutcome of 34th Annual General Meeting held on 31 July 2026
2026-07-31Concall / analyst meetLink of Recording
2026-07-31General UpdatesConclusion of the Board Meeting held today, i.e., 31 July 2026
2026-07-31Board meeting outcomeUnaudited Standalone and Consolidated Financial Results for Q1 of FY 2026-27
2026-07-29Press ReleaseA press release dated July 29, 2026, titled "Sun Pharma receives approval to manufacture and market semaglutide in Brazil".
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
Put / call open interest0.78
Max pain (expiry 2026-10-27)1,840
Largest call open interest at1,920
Largest put open interest at1,780
Implied volatility, at the money18.3%
Underlying at snapshot1,801.00
Open interest by strike around the price, nearest expiry. End-of-day NSE snapshot, 01-Oct-2026 15:40:00. Max pain is the strike where option buyers together would lose the most at expiry.
Trade dateShares sold short
2026-09-30172
2026-09-291,350
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2021-06-16NCLTSun Pharmaceutical Industries Ltd. Vs Allychem Laboraties Pvt. Ltd.
2021-05-25NCLATSun Pharmaceutical Industries & Anr VS Sumit Binani & Anr
2021-04-30NCLATSun Pharmaceutical Industries & Anr VS Sumit Binani & Anr
2021-02-05NCLTSun Pharmaceutical Industries Ltd. Vs Allychem Laboraties Pvt. Ltd.
2021-01-19NCLTSun Pharmaceutical Industries Ltd. Vs Allychem Laboraties Pvt. Ltd.
2020-11-11NCLTM/s. Sun Pharmaceutical Industries Ltd. Vs Allychem Laboratories Pvt. Ltd.
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Sun Pharmaceutical Industries Ltd?

Sun Pharmaceutical Industries Ltd (SUNPHARMA) has a market capitalisation of Rs 4,47,476 Cr. at the 2026-10-01 close.

What is the P/E ratio of Sun Pharmaceutical Industries Ltd?

Sun Pharmaceutical Industries Ltd trades at a P/E of 35.4 on trailing twelve-month profit, at the 2026-10-01 close.

What were Sun Pharmaceutical Industries Ltd's latest quarterly results?

In the Jun 2026 quarter, Sun Pharmaceutical Industries Ltd sales was Rs 15,300 Cr (+10.5% vs Jun 2025) and net profit was Rs 2,901 Cr.

What is the 52-week high and low of Sun Pharmaceutical Industries Ltd?

The 52-week high is Rs 2,046.90 and the 52-week low is Rs 1,583.70.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03